Table 2 Review all the studies concerning IHC markers of primary PEACs
Study | No. of cases | Immunohistochemical results | |||
|---|---|---|---|---|---|
CK-7 | TTF-1 | CK-20 | CDX2 | ||
Yousem [8] | 6 | 6+ | 6+ | 6− | 6− |
Inamura et al. [9] | 7 | 7+ | 3+/4− | 3+/4− | 5+/2− |
Li et al. [10] | 1 | 1− | 1− | 1+ | 1+ |
Hatanaka et al. [11] | 1 | 1− | 1− | 1+ | 1+ |
Maeda et al. [12] | 1 | 1+ | 1+ | 1− | NA |
Lin et al. [13] | 1 | 1+ | 1− | 1+ | 1− |
Qureshi et al. [14] | 1 | 1+ | 1− | 1+ | 1+ |
Wang et al. [15] | 9 | 9+ | 4+/5− | 2+/7− | 6+/3− |
Stojsic et al. [16] | 2 | 2− | 2− | 2+ | 2+ |
Laszlo et al. [17] | 1 | 1− | 1− | 1+ | 1+ |
Garajová et al. [18] | 2 | 1+/1− | 2− | 1+/1− | 2+ |
Metro et al. [19] | 1 | 1+ | 1− | 1− | 1+ |
Handa et al. [20] | 1 | 1+ | 1+ | 1− | 1− |
Nottegar et al. [4] | 46 | 46+ | 21+/25− | 15+/31− | 46+ |
Lin et al. [21] | 1 | 1− | 1− | 1+ | 1+ |
Matsushima et al. [22] | 8 | 7+/1− | 1+/7− | 7+/1− | 5+/3− |
Nottegar et al. [5] | 8 | 8+ | 1+/7− | 1+/7− | 8+ |
Sun et al. [23] | 1 | 1+ | 1− | 1− | 1+ |
Bian et al. [24] | 13 | 10+/3− | 7+/6− | 8+/5− | 8+/5− |
The present study | 18 | 16+/2− | 7+/11− | 17+/1− | 13+/5− |
Total | 129 | 116+/13− | 52+/77− | 62+/67− | 102+/26− |
Positive expression (%) | 89.9 | 40.3 | 48.1 | 79.1 | |